| ASOCIADOS-S-A |
ASOCIADOS-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| BELLAVISTA-S-A |
BELLAVISTA-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| B-THE-GROUP |
B-THE-GROUP |
62%
|
ment consolidation process, the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external co… |
| ECL-THE-GROUP |
ECL-THE-GROUP |
62%
|
gnized from the consolidated statement of financial position, because the Group transferred substantially all of the risks and rewards. Expected credit loss assessment for customers (ECL) The Group u… |
| ENFOCA-GROUP |
ENFOCA-GROUP |
62%
|
15 ( 4,022,294 ) ( 1,125,622 ) ( 4,520,827 ) Payment for lease liabilities 15 ( 43,851 ) ( 45,593 ) ( 42,530 ) Penalty paid for debt prepayment 15 ( 81 ) — ( 53,285 ) Payment for derivatives premiums… |
| FORWARD-PURCHASE-AGREEMENTS-THE-GROUP |
FORWARD-PURCHASE-AGREEMENTS-THE-GROUP |
62%
|
olling interest. X. Written Put and Call Options in Business Combinations and Forward Purchase Agreements The Group may write a put option or enter into a forward purchase agreement with non-controll… |
| GROUP-THE-GROUP |
GROUP-THE-GROUP |
62%
|
s are expensed as incurred. F-14 Table of Contents Auna S.A. and Subsidiaries Notes to the Consolidated Financial Statements December 31, 2025, 2024 and 2023 ii. Subsidiaries Subsidiaries are entitie… |
| INDET-LABORATORIO-CANTELLA-S-A |
INDET-LABORATORIO-CANTELLA-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| INDET-ONCOGENOMICS-S-A |
INDET-ONCOGENOMICS-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| INTERNATIONAL-FINANCE-CORPORATION |
INTERNATIONAL-FINANCE-CORPORATION |
62%
|
et of internal security controls, including password policies, access controls, and backup and restoration processes. Likewise, we are currently working on improving the internal control environment … |
| LABORATORIO-CANTELLA-S-A |
LABORATORIO-CANTELLA-S-A |
62%
|
— ( 738 ) — ( 738 ) Exchange difference 250,211 67,837 48,372 11,356 — 377,776 Balances as of December 31, 2023 2,069,238 478,531 450,964 256,154 23,778 3,278,665 Balances as of January 1, 2024 2,069… |
| LIMA-THE-GROUP |
LIMA-THE-GROUP |
62%
|
rehensive income on a straight-line basis as follows: Years Software 2 to 10 Customer relationships 10 to 18 Surface rights agreement 40 Assets that are subject to amortization are reviewed for impai… |
| MANAGEMENT-THE-GROUP |
MANAGEMENT-THE-GROUP |
62%
|
ts that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Evidence that a financial asset is credit-impaired includes the evaluation of all the follow… |
| MATERIAL-ACCOUNTING-POLICIES-THE-GROUP |
MATERIAL-ACCOUNTING-POLICIES-THE-GROUP |
62%
|
ial statements, Management has made judgments and estimates that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual… |
| MPMS-THE-GROUP |
MPMS-THE-GROUP |
62%
|
olling interest. X. Written Put and Call Options in Business Combinations and Forward Purchase Agreements The Group may write a put option or enter into a forward purchase agreement with non-controll… |
| ONCOGENOMICS-S-A |
ONCOGENOMICS-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| ONCOMEDICA-S-A |
ONCOMEDICA-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| RADIONCOLOGIA-S-A |
RADIONCOLOGIA-S-A |
62%
|
r 31, 2024, includes two trademarks “Doctors” and “OCA” for an amount of S/ 131,643 thousand and S/ 66,519 thousand, respectively (S/ 158,020 thousand and S/ 79,847 thousand, respectively as of Decem… |
| S-A-C-ONCOGENOMICS-S-A |
S-A-C-ONCOGENOMICS-S-A |
62%
|
udes the estimated market value of the contracts with insures for cardiology services and client services identified as a result of the acquisition of Hospital y Clínica OCA S.A. de C.V. , Patología … |
| WORLD-BANK-GROUP |
WORLD-BANK-GROUP |
62%
|
ended December 31, 2024. The increase in cash used was primarily driven by higher payments for the extinguishment of debt of S/64.8 million in 2025 compared to S/16.6 million in 2024, as well as lowe… |
